Metabolic Effects of Testosterone Replacement Therapy in Men with Functional Secondary Hypogonadism, Obesity and Type 2 Diabetes or Metabolic Syndrome: A Systematic Review
Medical Sciences · 22.07.2026 · 14 (3) · 418
DOI: 10.3390/medsci14030418 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Medical Sciences, online erschienen am 22.07.2026. Verfasst von Christos Ntais und 2 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology Program, School of Science and Technology, Hellenic Open University, 26335 Patras, Greece. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypogonadism, Testosterone, Metabolic Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/Objectives: Functional secondary hypogonadism is frequent in men with obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM), but whether testosterone replacement therapy (TRT) produces clinically relevant metabolic benefits remains uncertain. This systematic review evaluated double-blind randomized placebo-controlled trials of TRT in obese men with functional secondary hypogonadism and either T2DM or metabolic syndrome.
Methods
PubMed and Scopus were searched up to May 2026. Eligible studies enrolled adult men with biochemical hypogonadism and T2DM or metabolic syndrome, compared TRT with placebo, and reported metabolic outcomes. Open-label, single-blind, and non-randomized studies were excluded. Risk of bias was assessed with the Cochrane RoB 2 framework and certainty of evidence with GRADE.
Results
Eight trials were included. The most consistent signal was improvement in body composition, mainly increased lean mass and reduced fat mass. Effects on insulin resistance were favorable in several trials but heterogeneous. GRADE certainty was low for fat mass, lean mass, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and it was very low for clamp-derived insulin sensitivity, HbA1c, fasting glucose, lipid outcomes, inflammatory and vascular surrogate markers, and long-term safety.
Conclusions
Low-certainty evidence suggests that TRT may improve body composition and HOMA-IR in carefully selected men with functional secondary hypogonadism and metabolic disease, whereas effects on glycemic and lipid outcomes remain very uncertain. TRT should not be regarded as an antidiabetic or lipid-lowering intervention. Larger phenotype-specific trials with longer follow-up are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epidemiology Program, School of Science and Technology, Hellenic Open University, 26335 Patras, Greece.
- Department of Public Health, Medical School, University of Patras, 26504 Patras, Greece.
ORCID-Profile: Christos Ntais, Apostolos Vantarakis, Ioanna P Chatziprodromidou
Zitieren
APA
Ntais, C., Vantarakis, A., & Chatziprodromidou, I. P. (2026). Metabolic Effects of Testosterone Replacement Therapy in Men with Functional Secondary Hypogonadism, Obesity and Type 2 Diabetes or Metabolic Syndrome: A Systematic Review. Medical Sciences, 14(3), 418. https://doi.org/10.3390/medsci14030418
Vancouver
Ntais C, Vantarakis A, Chatziprodromidou IP. Metabolic Effects of Testosterone Replacement Therapy in Men with Functional Secondary Hypogonadism, Obesity and Type 2 Diabetes or Metabolic Syndrome: A Systematic Review. Medical Sciences. 2026;14(3):418. doi:10.3390/medsci14030418
BibTeX
@article{Ntais2026,
author = {Ntais, Christos and Vantarakis, Apostolos and Chatziprodromidou, Ioanna P},
title = {Metabolic Effects of Testosterone Replacement Therapy in Men with Functional Secondary Hypogonadism, Obesity and Type 2 Diabetes or Metabolic Syndrome: A Systematic Review},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {3},
pages = {418},
doi = {10.3390/medsci14030418}
}
EUVIMED